Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects
28 August 2020 (08:00 - 18:00)
Organised by:
Abstract
Slides
About the speaker
Peking University First Hospital, Beijing (China)
56 More presentations in this session
Doctor C. Becker (Wuppertal, DE)
Doctor S. Frechen (Leverkusen, DE)
Doctor D. Radenkovic (Greater London, GB)
Doctor P. Sulzgruber (Krems an der Donau, AT)
Access the full session
The Event
ESC Congress 2020
28 August 2020
08:00 CET
/f/125658/640x360/c39f4547b4/ett-s3-ep7.jpg)
